Swisspreneur Show EP #516 - Patrick Pestalozzi & François Capel: How This Biomarker Can Detect Sepsis 3 Days Early
Sep 3, 2025
In this discussion, Patrick Pestalozzi, CEO of Abionic and a seasoned leader in the medtech industry, shares insights into revolutionary sepsis detection technology. He explains how their product, abioSCOPE®, can identify sepsis up to 72 hours before symptoms appear, emphasizing its potential for improving emergency care. The conversation also delves into the challenges of innovating in health tech, navigating leadership transitions, and strategies to secure funding and succeed in international markets. François Capel contributes his expertise on fostering innovation in high-stakes environments.
AI Snips
Chapters
Transcript
Episode notes
Nanofluidics Enables Drop‑Of‑Blood Diagnostics
- Abionic uses nanofluidic technology to run lab-quality tests from a 50 µL finger-prick of blood.
- This enables rapid near-patient diagnostics with broad biomarker potential beyond current tests.
PSP As An Early Sepsis Marker
- Pancreatic stone protein (PSP) is Abionic's focused biomarker for early sepsis detection.
- PSP can give clinicians actionable early warning well before clinical recognition.
Founder Became Early Investor Then CEO
- Patrick invested as an angel in Abionic a decade before joining as CEO because he believed in the technology.
- That early bet later informed his decision to take on operational leadership to drive commercialization.